## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A INFORMATION**

# Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)

Filed b	y the Regist	trant $\ \Box$ Filed by a Party other than the Registrant $\ \Box$	
Check	the appropr	riate box:	
	Preliminary Proxy Statement		
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))		
	Definitive Proxy Statement		
<b></b>	Definitive Additional Materials		
	Soliciting	g Material under §240.14a-12	
		XERIS PHARMACEUTICALS, INC. (Name of Registrant as Specified in its Charter)	
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Payme	nt of Filing	Fee (Check the appropriate box):	
	No fee required.		
	Fee computed on the table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	Fee paid previously with preliminary materials.		
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.		
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	



## Xeris Pharmaceuticals, Inc. Important Notice Regarding the **Availability of Proxy Materials**

#### Stockholders Meeting to be held on June 08, 2021

For Stockholders as of record on April 19, 2021

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend meeting, go to: www.proxydocs.com/XERS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



## For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/XERS

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 28, 2021.

To order paper materials, use one of the following methods.



# INTERNET

www.investorelections.com/XERS

**TELEPHONE** (866) 648-8133



\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

## Xeris Pharmaceuticals, Inc.

Meeting Type: Annual Meeting of Stockholders

Date: Tuesday, June 08, 2021 Time: 08:00 AM, Central Daylight Time

Place: To be held virtually – please visit www.proxydocs.com/XERS for additional information on virtual meeting registration.

You must register to attend the meeting online and/or participate at www.proxydocs.com/XERS

SEE REVERSE FOR FULL AGENDA

# Xeris Pharmaceuticals, Inc.

**Annual Meeting of Stockholders** 

### THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR ON PROPOSALS 1 AND 2

#### PROPOSAL

- Election of Directors
   1.01 Paul R. Edick
  - 1.02 Marla S. Persky
- Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021.

To transact any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting.